selected publications
- Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine. Nature communications. 2020 Academic Article GET IT
-
Silibinin down-regulates PD-L1 expression in nasopharyngeal carcinoma by interfering with tumor cell glycolytic metabolism.
Archives of biochemistry and biophysics.
2020
Academic Article
GET IT
Times cited: 2 -
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce.
Journal for immunotherapy of cancer.
2020
Conference Paper
GET IT
Times cited: 4 -
CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors.
Nature immunology.
2020
Academic Article
GET IT
Times cited: 29 - In vitro assays for effector T cell functions and activity of immunomodulatory antibodies. Methods in enzymology. 2019 Article GET IT
-
In situ vaccination with defined factors overcomes T cell exhaustion in distant tumors.
The Journal of clinical investigation.
2019
Academic Article
GET IT
Times cited: 6 - Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. Journal for immunotherapy of cancer. 2019 Conference Paper GET IT
-
Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop.
Journal for immunotherapy of cancer.
2019
Conference Paper
GET IT
Times cited: 23 -
Rational design of anti-GITR-based combination immunotherapy.
Nature medicine.
2019
Academic Article
GET IT
Times cited: 37 - Correction to: Strategies for Predicting Response to Checkpoint Inhibitors. Current hematologic malignancy reports. 2019 Article GET IT
-
Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies.
Cancer cell.
2018
Academic Article
GET IT
Times cited: 19 -
Non-conventional Inhibitory CD4+Foxp3-PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity.
Cancer cell.
2018
Academic Article
GET IT
Times cited: 2 -
Strategies for Predicting Response to Checkpoint Inhibitors.
Current hematologic malignancy reports.
2018
Review
GET IT
Times cited: 8 -
Non-conventional Inhibitory CD4+Foxp3-PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity.
Cancer cell.
2018
Academic Article
GET IT
Times cited: 48 -
Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies.
Cancer cell.
2018
Review
GET IT
Times cited: 137 -
Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer.
Nature.
2017
Academic Article
GET IT
Times cited: 319 -
Microenvironment modulation and enhancement of antilymphoma therapy by the heparanase inhibitor roneparstat.
Hematological oncology.
2017
Letter
GET IT
Times cited: 10 - Interfering with Helios-induced regulatory T cell stability as a strategy for cancer immunotherapy. Translational cancer research. 2016 Editorial Article GET IT
-
Immunotherapy advances in uro-genital malignancies.
Critical reviews in oncology/hematology.
2016
Review
GET IT
Times cited: 16 -
Lymphoma Immunotherapy: Current Status.
Frontiers in immunology.
2015
Review
GET IT
Times cited: 27 -
Alphavirus-based vaccines in melanoma: rationale and potential improvements in immunotherapeutic combinations.
Immunotherapy.
2015
Review
GET IT
Times cited: 2 -
The New Era of Cancer Immunotherapy: Manipulating T-Cell Activity to Overcome Malignancy.
2015
GET IT
Times cited: 26 -
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
Science (New York, N.Y.).
2015
Academic Article
GET IT
Times cited: 3833 -
HSPH1 inhibition downregulates Bcl-6 and c-Myc and hampers the growth of human aggressive B-cell non-Hodgkin lymphoma.
Blood.
2015
Academic Article
GET IT
Times cited: 20 -
Activated d16HER2 homodimers and SRC kinase mediate optimal efficacy for trastuzumab.
Cancer research.
2014
Academic Article
GET IT
Times cited: 38 -
Sialidase NEU4 is involved in glioblastoma stem cell survival.
Cell death & disease.
2014
Academic Article
GET IT
Times cited: 12 -
Pleiotropic antitumor effects of the pan-HDAC inhibitor ITF2357 against c-Myc-overexpressing human B-cell non-Hodgkin lymphomas.
International journal of cancer.
2014
Academic Article
GET IT
Times cited: 15 -
Combination of alphavirus replicon particle-based vaccination with immunomodulatory antibodies: therapeutic activity in the B16 melanoma mouse model and immune correlates.
Cancer immunology research.
2014
Academic Article
GET IT
Times cited: 16 - Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5-7, 2012. Cancer immunology, immunotherapy : CII. 2013 Article GET IT
-
Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target.
Blood.
2011
Academic Article
GET IT
Times cited: 21 -
Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death.
Cancer research.
2010
Academic Article
GET IT
Times cited: 91 -
Tumor-reactive CD8+ early effector T cells identified at tumor site in primary and metastatic melanoma.
Cancer research.
2010
Academic Article
GET IT
Times cited: 30 -
Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study.
Blood.
2008
Academic Article
GET IT
Times cited: 90 -
The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells.
Haematologica.
2008
Academic Article
GET IT
Times cited: 41